Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Sonnet BioTherapeutics Holdings, Inc is a biotechnology business based in the US. Sonnet BioTherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Sonnet BioTherapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Social investors
| Latest market close | $1.55 |
|---|---|
| 52-week range | $1.00 - $4.29 |
| 50-day moving average | $1.40 |
| 200-day moving average | $2.04 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-66.46 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.55 from 2021-05-28
| 1 week (2021-07-25) | N/A |
|---|---|
| 1 month (2021-07-02) | 2.65% |
| 3 months (2021-05-05) | -17.99% |
| 6 months (2021-02-01) | N/A |
| 1 year (2020-08-01) | N/A |
|---|---|
| 2 years (2019-08-01) | N/A |
| 3 years (2018-08-01) | N/A |
| 5 years (2016-08-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -356.91% |
| Return on equity TTM | -27822.18% |
| Profit margin | 0% |
| Book value | $0.10 |
| Market capitalisation | $24 million |
TTM: trailing 12 months
There are currently 2.1 million Sonnet BioTherapeutics shares held short by investors – that's known as Sonnet BioTherapeutics's "short interest". This figure is 48.7% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Sonnet BioTherapeutics shares can be evaluated.
Sonnet BioTherapeutics's "short interest ratio" (SIR) is the quantity of Sonnet BioTherapeutics shares currently shorted divided by the average quantity of Sonnet BioTherapeutics shares traded daily (recently around 808893.10344828). Sonnet BioTherapeutics's SIR currently stands at 2.61. In other words for every 100,000 Sonnet BioTherapeutics shares traded daily on the market, roughly 2610 shares are currently held short.
However Sonnet BioTherapeutics's short interest can also be evaluated against the total number of Sonnet BioTherapeutics shares, or, against the total number of tradable Sonnet BioTherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sonnet BioTherapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Sonnet BioTherapeutics shares in existence, roughly 100 shares are currently held short) or 0.1133% of the tradable shares (for every 100,000 tradable Sonnet BioTherapeutics shares, roughly 113 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sonnet BioTherapeutics.
Find out more about how you can short Sonnet BioTherapeutics stock.
We're not expecting Sonnet BioTherapeutics to pay a dividend over the next 12 months.
Sonnet BioTherapeutics's shares were split on a 1:26 basis on 1 April 2020. So if you had owned 26 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet BioTherapeutics shares – just the quantity. However, indirectly, the new 2500% higher share price could have impacted the market appetite for Sonnet BioTherapeutics shares which in turn could have impacted Sonnet BioTherapeutics's share price.
Sonnet BioTherapeutics Holdings, Inc. , an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc.
Everything we know about the Chobani IPO, plus information on how to buy in.
Everything we know about the Stronghold Digital Mining IPO, plus information on how to buy in.
Everything we know about the ROX Financial LP IPO, plus information on how to buy in.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
